

Kuva intends to provide new fully funded offer to Lisata Therapeutics

HOUSTON, TX, UNITED STATES, August 21, 2026 /EINPresswire.com/ -- Kuva Labs, Inc. ("Kuva"), a clinical-stage oncology company, today announced its intention to submit a new fully funded offer to the Board of Directors of Lisata Therapeutics, Inc. ("Lisata") no later than August 31, 2026.

As previously announced, Kuva's prior proposed transaction with Lisata was terminated when Kuva was unable to complete the financing necessary to fund the transaction and Lisata declined Kuva's request for an extension of the tender offer period. Such extension was requested following Kuva's discovery of the omission of certain information they believed material, including certain clinical trial agreements, operational liabilities, and data relevant to trial outcomes. Based upon the internal analysis and ongoing discussions, Kuva remains interested in entering into a transaction with Lisata in accordance with Lisata's announced strategic goals.

Kuva has validated the strategic and scientific rational for combining the Kuva and Lisata technologies. Kuva believes that Lisata has failed to achieve its primary endpoints in its Phase 2 trials, likely due the inability to stratify patients entering the trial. Kuva NanoMark technology can resolve this challenge, identifying those patients that will respond well to treatment with Certepetide, accessing the true latent value of Certepetide.

"As we have always believed, based upon Kuva's ability to accurately stratify patients who will strongly benefit from Certepetide, we believe a fully funded, timely offer is the best path to deliver value to Lisata's shareholders and to bring this technology to patients as quickly as possible," said Mark Land, CEO of Kuva Labs.

Kuva intends to deliver its formal offer to Lisata's Board of Directors on or before August 31, 2026, and will provide further updates as appropriate.

Mark Land
Kuva Labs, Inc
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/935940677>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.